Tildrakizumab
Tildrakizumab
Tildrakizumab (pronounced as til-dra-ki-zu-mab) is a monoclonal antibody designed for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It is marketed under the brand name Ilumya in the United States and Ilumetri in Europe.
Etymology
The name Tildrakizumab is derived from the International Union of Pure and Applied Chemistry (IUPAC) nomenclature for antibodies. The "til" prefix indicates the drug's human origin, "dra" refers to the drug's relevance to the immune system, "ki" denotes the drug's targeting of the interleukin (IL) system, and "zu" signifies the drug's humanized antibody type. The "mab" suffix is common to all monoclonal antibodies.
Mechanism of Action
Tildrakizumab works by binding to the p19 subunit of interleukin 23 (IL-23), a cytokine that plays a crucial role in inflammatory processes and is thought to be linked to psoriasis. By inhibiting IL-23, Tildrakizumab can reduce inflammation and slow the rapid growth of skin cells that causes psoriasis plaques.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Psoriasis: A skin disease that causes red, itchy scaly patches, most commonly on the knees, elbows, trunk and scalp.
- Interleukin 23: A cytokine that plays a key role in managing the immune system and inflammation.
- Cytokine: A type of protein that plays an important role in cell signaling and can influence the immune system.
External links
- Medical encyclopedia article on Tildrakizumab
- Wikipedia's article - Tildrakizumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski